Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Other Accumulated Expenses (2022 - 2026)

Sagimet Biosciences' Other Accumulated Expenses history spans 5 years, with the latest figure at $15000.0 for Q1 2026.

  • Quarterly Other Accumulated Expenses fell 6.25% to $15000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $15000.0 through Mar 2026, down 6.25% year-over-year, with the annual reading at $27000.0 for FY2025, 440.0% up from the prior year.
  • Other Accumulated Expenses came in at $15000.0 for Q1 2026, down from $27000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $233000.0 in Q4 2023 to a low of $1000.0 in Q2 2025.
  • The 5-year median for Other Accumulated Expenses is $15500.0 (2025), against an average of $48416.7.
  • Year-over-year, Other Accumulated Expenses plummeted 97.85% in 2024 and then soared 440.0% in 2025.
  • Sagimet Biosciences' Other Accumulated Expenses stood at $57000.0 in 2022, then skyrocketed by 308.77% to $233000.0 in 2023, then tumbled by 97.85% to $5000.0 in 2024, then skyrocketed by 440.0% to $27000.0 in 2025, then tumbled by 44.44% to $15000.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Other Accumulated Expenses are $15000.0 (Q1 2026), $27000.0 (Q4 2025), and $8000.0 (Q3 2025).